|
|
Background: Although long non-coding RNA LINC00511 has emerged as an oncogene and was reported to be a poor prognosticator in cancer, the results remain uncharacterized. Hence, for the first time, we sought to clarify the association between LINC00511 and clinical outcomes in malignant tumors.
Methods: We conducted a detailed search of PubMed and Web of Science online databases for all eligible studies. A meta-analysis was performed using Stata 12.0 software. Based on TCGA datasets, the prognostic power of high LINC00511 expression in cancer was analyzed using Kaplan-Meier survival curves.
Results: Fifteen studies containing 1,356 individuals were eventually included in the current analysis. Compared with low LINC00511 expression, high LINC00511 expression was closely correlated with tumor size (OR = 2.46, 95% CI: 1.40 - 4.31, p = 0.001) tumor stage (OR = 2.52, 95% CI: 1.91 - 3.33, p = 0.000), lymph node metastasis (OR = 2.97, 95% CI: 2.22 - 3.97, p = 0.000), distant metastasis (OR = 2.09, 95% CI: 1.08 - 4.03, p = 0.028), and histological differentiation (OR = 1.29, 95% CI 1.00 - 1.66, p = 0.047) in cancer. TCGA data manifested that high LINC00511 expression was markedly associated with worse OS (HR = 1.9, p = 0.000) among tumor patients.
Conclusions: Thus, the increased expression level of LINC00511 was associated with more advanced clinicopathological features and poor prognosis as a novel predictive biomarker in various cancers.
DOI: 10.7754/Clin.Lab.2020.200615
|
